Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy.

On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s potential as a differentiated antibody-drug conjugate (ADC), estimating a commercial opportunity exceeding $1 billion in later-line settings, with significantly larger upside as the drug advances into earlier treatment lines.

The same day, Guggenheim also raised its price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $15 from $10, reiterating a Buy rating. The firm noted that updated clinical data at both tested dose levels materially outperformed current standards of care, prompting an increase in its estimated probability of success to 60% from 30%. This meaningful improvement in clinical confidence, combined with strong efficacy signals, reinforces the asset’s potential to become a best-in-class therapy.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing conditionally activated PROBODY® therapeutics designed to target tumors while limiting systemic toxicity. With increasingly compelling clinical data and rising analyst conviction, the company appears well-positioned to unlock significant value as its pipeline advances, upporting a favorable risk-reward profile for investors seeking exposure to innovative oncology assets.

READ NEXT: 11 Most Undervalued Renewable Energy Stocks to Invest In and 10 Best New AI Stocks to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.